Clinical Trials Logo

Filter by:
NCT ID: NCT06188468 Recruiting - Solid Tumor Clinical Trials

ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

The objective of the study is to construct a noninvasive approach 68Ga-THP-Trop2 VHH PET/CT to detect the Trop-2 expression of tumor lesions in patients with Solid tumors and to identify patients benefiting from Trop-2 targeting antibody-drug conjugate treatment.

NCT ID: NCT06188429 Recruiting - ASD Clinical Trials

Peripheral Blood VA/TREM2 Levels and Their Correlation Analysis With the Development and Autistic Symptoms in Children With ASD

PBVTLCAASD
Start date: November 20, 2023
Phase:
Study type: Observational

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder characterized by social impairment, repetitive behaviors, and narrow interests. With advancements in diagnostic techniques, the prevalence of ASD has been increasing annually. However, due to its complex and diverse etiology, there is no definitive consensus on the pathogenic mechanism of ASD. Numerous studies indicate that genetics, environment, and other factors play crucial roles in the onset of ASD. Vitamin A (VA) exerts its effects in the body through its active metabolite, retinoic acid (RA), which regulates the transcriptional activity and expression of downstream genes by binding to retinoic acid receptors (RARs/RXRs). Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) is an immunoglobulin-like receptor present on microglial cells, with functions including inhibiting the production of inflammatory factors and engulfing apoptotic neurons. Recent foreign studies show a significant decrease in TREM2 levels in the brain tissue of ASD patients. However, there is limited research on the relationship between TREM2 and ASD. In our previous animal experiments, we observed a reduction in TREM2 in the prefrontal cortex of the brain in ASD model rats. Administering overexpressed TREM2 improved autism-like behavior in ASD model rats, and supplementing RA upregulated the expression of RA-RARα and TREM2, modulated microglial cell activation, and improved autism-like behavior in rats. Therefore, we believe that the RA/RARα pathway regulates the TREM-2 signaling pathway, mediating changes in microglial cells, and TREM2 may be involved in the pathogenesis of ASD. Soluble TREM2 (sTREM2) is formed by the extracellular domain shedding of TREM2 under the action of ADAM protease. Research indicates that the expression of sTREM2 can be detected in cerebrospinal fluid and plasma. However, the connection between VA, sTREM2 levels, and the behavioral and developmental levels of children with ASD remains unclear and requires further clinical research to validate. This will help deepen our understanding of TREM2 expression in ASD, its potential biological functions, and the role of RA.

NCT ID: NCT06188377 Recruiting - Healthy Clinical Trials

Application of Bioimpedance Vector Analysis in Neonates

Start date: November 6, 2023
Phase:
Study type: Observational

The goal of this observational study is to learn about the distribution of bioimpedance vector of healthy neonates in China in health conditions. The main question it aims to answer are:whether the distribution of bioimpedance vector of healthy neonates in China is correspond to that in other countries.Participants will be measures by NUTRILAB impedance analyzer (Akern, Florence, Italy).

NCT ID: NCT06188351 Recruiting - Atrial Fibrillation Clinical Trials

Three Dimensional Navigation IntraCardiac Guidance Kit for Atrial Septal Puncture

Start date: April 24, 2023
Phase: N/A
Study type: Interventional

This study aims to evaluate the safety and efficacy of a three-dimensional navigation intracardiac guidance kit to perform atrial septal puncture in patients requiring catheter ablation, which will be compared with procedures using traditional kit for atrial septal puncture.

NCT ID: NCT06187961 Recruiting - Clinical trials for Hepatocellular Carcinoma Non-resectable

Combined HAIC, Lenvatinib and Cadonilimab as Conversion Therapy for Unresectable Hepatocellular Carcinoma

CCGLC-011
Start date: December 1, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, phase 2 study. The purpose of study is to evaluate the feasibility and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and cadonilimab as conversion therapy for unresectable hepatocellular carcinoma.

NCT ID: NCT06187935 Recruiting - Clinical trials for Pulmonary Nodules, Solitary

Early Adjuvant Diagnosis of Pulmonary Nodules Based on CTC.

Start date: March 1, 2018
Phase:
Study type: Observational

The goal of this observational clinical trial is to evaluate the value of circulating tumor cell detection in the early diagnosis of malignant pulmonary nodule. The main questions it aims to answer is: the sensitivity and specificity of peripheral blood circulating tumor cell detection in differentiating benign and malignant pulmonary nodules (<3cm). Participants will be asked provide 4mL of peripheral blood for the test.

NCT ID: NCT06187740 Recruiting - Clinical trials for Small Cell Lung Cancer Extensive Stage

Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy

Start date: December 1, 2023
Phase: Phase 1
Study type: Interventional

This study intends to recruit ES-SCLC patients with response to standard first-line chemo-immunotherapy to assess the safety of receiving different doses of consolidative thoracic radiotherapy.

NCT ID: NCT06187727 Recruiting - Heart Failure Clinical Trials

Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction

Health
Start date: July 1, 2023
Phase: Phase 4
Study type: Interventional

This Randomized controlled intervention study recruited patients diagnosed with ST-segment elevation myocardial infarction (STEMI). A total of 240 patients were enrolled in either Henagliflozin group or control group. Patients in Henggliflozin group will be given by oral administration of Henggliflozin for 6 months post acute myocardial infarction. Prior to procedure, dynamic changes in myocardial enzymes were monitored. Major cardiovascular events, including non-fatal myocardial infarction, all-cause death, revascularization due to angina, and hospitalization for acute heart failure. This study aims to assess the impact of Henggelizin intervention on the reduction of myocardial infarction size (evaluated by cardiac enzyme) and improvement of left ventricular remodeling in patients with ST-segment elevation myocardial infarction.

NCT ID: NCT06187597 Recruiting - Clinical trials for Locally Advanced Esophageal Squamous Cell Carcinoma

Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)

EC-CRT-007
Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

Although definitive chemoradiotherapy (CRT) is the standard treatment option for unresectable locally advanced esophageal cancer, elderly patients tolerate intravenous concurrent CRT less well with age and comorbidities. Previous trials have demonstrated that CRT with oral S-1 was tolerable and provided significant survival benefits over radiotherapy alone in elderly patients with esophageal squamous cell carcinoma (ESCC). However, as high as 54% of patients with elderly ESCC experienced locoregional or distant recurrence after CRT. Therefore, a more effective regimen for older patients is needed. Immune checkpoint inhibitors targeting PD-1/PD-L1 have shown substantial clinical benefits in advanced esophageal cancer. Recently, the combination of immunotherapy with CRT has emerged as a promising strategy to improve clinical outcomes in locally advanced esophageal cancer. The aim of this study was to evaluate the efficacy and safety of toripalimab (an anti-PD-1 antibody) after concurrent CRT in elderly patients with locally advanced ESCC.

NCT ID: NCT06186947 Recruiting - COVID-19 Clinical Trials

Effects of COVID-19 Infection on Pregnancy Outcomes and Offspring Health

Start date: September 1, 2022
Phase:
Study type: Observational

This is a large observational cohort study to assess the impact of COVID-19 infection on pregnancy outcomes and offspring health.